112 related articles for article (PubMed ID: 2560915)
1. In vitro neutralization of antigenic variants of bluetongue virus is related to in vivo protection.
Sundin DR; Dean VC; DuBard KM; Mecham JO
Viral Immunol; 1989; 2(3):195-203. PubMed ID: 2560915
[TBL] [Abstract][Full Text] [Related]
2. Conformationally dependent epitopes of bluetongue virus neutralizing antigen.
Grieder FB; Schultz KT
Viral Immunol; 1989; 2(1):17-24. PubMed ID: 2472808
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to bluetongue virus define two neutralizing epitopes and a hemagglutinating epitope.
Mecham JO; Jochim MM
Viral Immunol; 1990; 3(2):161-70. PubMed ID: 1694430
[TBL] [Abstract][Full Text] [Related]
4. Laboratory evaluation of a living attenuated vaccine against bluetongue type 20 virus.
Wark MC; Shepherd-Clark MB; Smith HV; Collins WD
Aust Vet J; 1982 Jul; 59(1):6-10. PubMed ID: 6293439
[TBL] [Abstract][Full Text] [Related]
5. Role of neutralising antibody in passive immunity to bluetongue infection.
Jeggo MH; Wardley RC; Taylor WP
Res Vet Sci; 1984 Jan; 36(1):81-6. PubMed ID: 6324311
[TBL] [Abstract][Full Text] [Related]
6. Immunologic response of sheep to inactivated and virulent bluetongue virus.
Stott JL; Barber TL; Osburn BI
Am J Vet Res; 1985 May; 46(5):1043-9. PubMed ID: 2988376
[TBL] [Abstract][Full Text] [Related]
7. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup.
White JR; Eaton BT
J Gen Virol; 1990 Jun; 71 ( Pt 6)():1325-32. PubMed ID: 1693664
[TBL] [Abstract][Full Text] [Related]
8. Identification of four distinct neutralizing epitopes on bluetongue virus serotype 10 using neutralizing monoclonal antibodies and neutralization-escape variants.
Heidner HW; Rossitto PV; MacLachlan NJ
Virology; 1990 Jun; 176(2):658-61. PubMed ID: 1693250
[TBL] [Abstract][Full Text] [Related]
9. Clinical and serological response of sheep to serial challenge with different bluetongue virus types.
Jeggo MH; Gumm ID; Taylor WP
Res Vet Sci; 1983 Mar; 34(2):205-11. PubMed ID: 6304836
[TBL] [Abstract][Full Text] [Related]
10. Potency and efficacy of inactivated bluetongue virus vaccines.
Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of neutralization-related epitopes within a bluetongue virus serotype.
Letchworth GJ; Appleton JA
Virology; 1983 Jan; 124(2):300-7. PubMed ID: 6186077
[TBL] [Abstract][Full Text] [Related]
12. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody analysis of serotype-restricted and unrestricted bluetongue viral antigenic determinants.
Appleton JA; Letchworth GJ
Virology; 1983 Jan; 124(2):286-99. PubMed ID: 6186076
[TBL] [Abstract][Full Text] [Related]
14. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
[TBL] [Abstract][Full Text] [Related]
15. A complex neutralization domain of bluetongue virus serotype 17 defines a virulence-associated marker.
Bernard KA; Israel BA; Schultz KT
Viral Immunol; 1996; 9(2):97-106. PubMed ID: 8822626
[TBL] [Abstract][Full Text] [Related]
16. An experimental inactivated vaccine against bluetongue.
Parker J; Herniman KA; Gibbs EP; Sellers RF
Vet Rec; 1975 Mar; 96(13):284-7. PubMed ID: 165609
[TBL] [Abstract][Full Text] [Related]
17. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep.
Huismans H; van der Walt NT; Cloete M; Erasmus BJ
Virology; 1987 Mar; 157(1):172-9. PubMed ID: 3029956
[TBL] [Abstract][Full Text] [Related]
18. Bluetongue vaccine: cells and/or antibodies.
Jeggo MH; Wardley RC
Vaccine; 1985 Mar; 3(1):57-8. PubMed ID: 2988227
[TBL] [Abstract][Full Text] [Related]
19. Immunochemical analyses of Australian bluetongue virus serotypes using monoclonal antibodies.
White JR; Breschkin AM; Della-Porta AJ
Prog Clin Biol Res; 1985; 178():397-405. PubMed ID: 2989877
[TBL] [Abstract][Full Text] [Related]
20. The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine.
Huismans H
Onderstepoort J Vet Res; 1985 Sep; 52(3):149-51. PubMed ID: 3003649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
